Investment analysts at JPMorgan Chase & Co. dropped their target price on shares of VIVUS (NASDAQ:VVUS) from $8.00 to $5.00 in a note issued to investors on Tuesday, Stock Ratings Network reports. JPMorgan Chase & Co.’s price target would indicate a potential downside of 10.15% from the company’s current price. VIVUS, Inc. (NASDAQ:VVUS)stock performance was 7.23% in last session and finished the day at $ 5.5650. Traded volume was 10,887,712 shares in the last session and the average volume of the stock remained 3,606,540 shares. The beta of the stock remained 1.53. VIVUS, Inc. (NASDAQ:VVUS) insider ownership is 0.10%.

Arena Pharmaceuticals (NASDAQ:ARNA)’s shares have received a consensus recommendation of “Hold” from the nine analysts that are presently covering the stock, Stock Ratings Network reports. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)dropped 0.44% to $ 6.85 yesterday on volume of 8,441,293 shares. The intra-day range of the stock was $ 6.85 – 7.15. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)has a market capitalization of $ 1.50 billion.

Ariad Pharmaceuticals (NASDAQ:ARIA) announced its earnings results on Wednesday. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.05, StockRatingsNetwork reports. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s stock on May 6, 2014 reported a decrease of – 7.08% to the closing price of $ 7.09. Its fifty two weeks range is $ 2.15 – 23.00. The total market capitalization recorded $ 1.32 billion. The overall volume in the last trading session was 11,456,305 shares. In its share capital, Ariad Pharmaceuticals, Inc.(NASDAQ:ARIA) has 186.80 million outstanding shares.

Gilead Sciences (NASDAQ:GILD) CFO Robin L. Washington unloaded 27,600 shares of Gilead Sciences stock on the open market in a transaction dated Thursday, May 1st. The shares were sold at an average price of $79.16, for a total value of $2,184,816.00.On Friday, shares of Gilead Sciences, Inc. (NASDAQ:GILD) dropped 1.89% to close the day at $ 78.32. Company return on investment (ROI) is 18.70% and its monthly performance is recorded as 8.48% .Gilead Sciences, Inc. (NASDAQ:GILD) quarterly revenue growth is -4.51%.